“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra
From Washington, DC
- The American Hospital Association News reports,
- “The Senate Appropriations Committee Nov. 17 released its version of the fiscal year 2027 appropriations bill for the departments of Labor, Health and Human Services, Education and other agencies. The draft funding bill provides $112 billion in discretionary spending for the Department of Health and Human Services, a $3 billion reduction from FY 2026 enacted funding levels.”
- Here’s a link to the FY 2027 appropriations bill tracker from the government shutdown tracker website.
- Roll Call relates,
- “House Minority Leader Hakeem Jeffries won a closed-door vote of the Democratic caucus Wednesday setting him up to be the nation’s first Black speaker of the House, a historic step that follows Democrats’ staggering election wins earlier this month.
- “Jeffries, who had called for a recorded vote of the more than 250-member caucus that will serve in the next Congress despite facing no announced opponent, won decisively, 251-11. The margin suggests Jeffries will easily surpass the necessary 218 votes he will need on the House floor when the full chamber votes in January.”
- The Washington Post tells us,
- “A key vote on the nomination of Jim O’Neill to lead the nation’s science funding agency was abruptly pulled Wednesday morning amid concerns from the chairman of the committee that was considering his candidacy.
- “O’Neill had served in the No. 2 slot at the Department of Health and Human Services under Robert F. Kennedy Jr. from June 2025 to February, as well as the acting head of the Centers for Disease Control and Prevention for roughly five months. Sen. Bill Cassidy (R-Louisiana), chair of the Senate Health, Education, Labor and Pensions Committee, said Wednesday that he had concerns that O’Neill “did not do enough to stand up for science and against irresponsible decisions and statements from Secretary Kennedy.”
- STAT News informs us,
- “A little-known but influential panel that recommends which preventive services must be covered by insurance will meet this week for the first time in more than a year, with a membership overhauled by health secretary Robert F. Kennedy Jr.
- “The U.S. Preventive Services Task Force will meet to review recommendations related to cervical cancer, perinatal depression, and unhealthy alcohol use in teens and adults, all of which have not been updated in at least five years, and have been awaiting finalization since last year, when Kennedy canceled the group’s meetings.
- “The task force will also hear an “evidence presentation on healthy lifestyles to prevent cardiovascular disease in adults,” and hear presentations from subject matter experts on screening for chronic kidney disease, colorectal cancer, and lung cancer, as well as a discussion on “task force methods,” according to a notice sent Wednesday by the Agency for Healthcare Research and Quality.”
- The American Hospital Association News notes,
- “The Centers for Medicare & Medicaid Services has released a participant readiness checklist for its mandatory Comprehensive Care for Joint Replacement Expanded Model, or CJR-X. The checklist outlines actions hospitals can take prior to the model’s start date of Jan. 1, 2028. It also includes upcoming activities, tentative timelines and resources to support preparation for the model. CJR-X focuses on lower extremity joint replacement procedures.”
From the U.S. Office of Personnel Managemen front,
- Govexec reports,
- “Scott Kupor, the director of the Office of Personnel Management, said Tuesday his office is working on department-specific opportunities within the U.S. Tech Force, similar to the dedicated NASA track unveiled earlier this year.
- “We’re now finding other agencies who say, ‘hey look, I’ve got a particular focus in a cyber, or in some particular type of, engineer that’s bespoke to the agency we’re looking for,’” Kupor said at FedScoop’s FedTalks 2026 conference.
- “We’re going to augment the program with those types of activities,” he added.
- Kupor said the OPM is not ready to announce department-specific Tech Force tracks.
- FedWeek relates,
- “OPM has updated its guide to reductions in force that serves both as a blueprint for agencies in deciding whether to conduct them and how to carry them out, and for employees to look for potential challenge actions affecting them.
- “The Workforce Reshaping Handbook, attached to a memo to agencies, incorporates changes the Trump administration has made to both the process and appeal rights.”
- FedSmith tells us,
- “What Federal Retirees Will Pay for Medicare Part B in 2027
- “How much of your 2027 COLA will Medicare take? The new Part B premium, deductible and IRMAA brackets, plus what they mean for FEHB and PSHB retirees.”
- “What Federal Retirees Will Pay for Medicare Part B in 2027
- FedWeek also explains “How FEDVIP, FSAs (New Debit Card) Fit with FEHB and PSHB,”
From the U.S. Food and Drug Administration front,
- BioPharma Dive reports,
- “On Tuesday, a published report from Axios indicated that the White House abandoned the effort after it appeared Overton wasn’t likely to succeed. At Wednesday’s hearing, Committee Chairman and Louisiana Republican Senator Bill Cassidy confirmed that outcome and expressed surprise, stating he’d been involved in “productive conversations” that had “convinced me that she would follow the science and push back against decisions that put Americans’ lives at risk.”
- “I think she would have had the votes to pass out of a committee and to pass the full Senate,” Cassidy said at the hearing. “Unfortunately, with the limited time left, confirming a permanent FDA commissioner appears to fall to Senate Democrats.”
- “The decision is likely to set back for months the Trump administration’s efforts to nominate a permanent FDA commissioner. That position has been occupied on an acting basis since May by Kyle Diamantas, the agency’s deputy commissioner for food. His elevation came after the resignation of Marty Makary, who stepped down following a rocky tenure marred by constant leadership upheaval and unpredictable decisionmaking.
- “As an acting commissioner, Diamantas is only eligible under federal law to serve for 210 days. However, Overton’s withdrawal resets the 210-day clock.”
- Beckers Hospital Review relates,
- “The FDA is proposing to withdraw the liquid formulation of simvastatin, known as FloLipid, from the market after Salerno Pharmaceuticals failed to file required annual reports, according to a Nov. 18 notice in the Federal Register.
- “The FDA annual reports convey labeling information and technicalities, including updates on labeling and on chemistry, manufacturing and controls, according to FDA policy. The agency is giving Salerno Pharma the opportunity to request a hearing if it wants to argue why the approval should not be withdrawn.
- “The FDA approved FloLipid in April 2016. Salerno marketed it as the first liquid statin available in the U.S., an option for patients who have trouble swallowing pills. Generic simvastatin tablets remain widely available.”
- and
- “The FDA has launched the Global Reliance Disclosure Program, which allows drug and biologic applicants to share the agency’s minimally redacted approval packages with health authorities outside the U.S. The goal is to allow foreign regulators to rely on the FDA’s reviews instead of conducting duplicate evaluations while retaining their own authority over regulatory decisions.
- “The program began Oct. 30 with a PEPFAR tentative approval for lenacapavir, a drug for HIV prevention and treatment, and is currently available only for products with PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug applications. The FDA said it intends to expand the program in January 2027 to all novel drugs and biologics, including new molecular entity applications and original biologics license applications, according to a Nov. 17 news releas.”
- Reuters tells us,
- “The US FDA on Wednesday approved Sanofi’s (SASY.PA) oral drug venglustat, making it the first treatment for a type of rare genetic condition that affects the brain and nervous system, the health regulator said.
- “The drug, branded as Infilbray, was approved for adults and children weighing at least 15 kilograms, or about 33 pounds, with type 3 Gaucher disease, a rare inherited disorder that causes fatty substances to build up in the body and brain.”
From the public health and medical / Rx research front,
- The Wall Street Journal reports,
- “The U.S.’s loss of what is known as measles-elimination status is a massive public-health defeat that begs a question: How long will it take to regain it?
- “Based on other countries’ experience it could be up to five years, say doctors and epidemiologists. But that assumes the federal government is a robust and willing participant proactively working on measles vaccination.
- “Without that, it could take even longer.” * * *
- “Over the past few years, however, cases started to mount and outbreaks multiplied, reaching levels not seen since before measles was eliminated.
- “Both Brazil and Venezuela took about five years to regain their measles-elimination status, notes Dr. Amesh Adalja, a senior scholar at Johns Hopkins University and infectious-disease physician in Pennsylvania.
- “It’s not something that happens overnight,” says Adalja. “Right now in the United States you can’t even start the clock yet until we have 12 months without continual spread of the same genetic strain of the virus. These outbreaks have to stop first.”
- Beckers Hospital Review relates,
- “The Leapfrog Group has given 11 hospitals their 30th consecutive “A” safety grade and three hospitals an “F” in its fall 2026 Hospital Safety Grade update, released Nov. 18.
- “Leapfrog, a national patient safety nonprofit, grades general acute care hospitals twice a year, in the spring and fall, on how well they protect patients from preventable errors, injuries, accidents and infections. Each hospital receives a numerical score that Leapfrog converts to a letter grade from A to F. Scores draw on up to 22 measures from CMS, results from the voluntary Leapfrog Hospital Survey and supplemental data. Read more about Leapfrog’s fall 2026 methodology here.
- “Of the 729 hospitals that earned an “A” when Leapfrog issued its first grades in June 2012, 11 have held the top grade in every cycle since. The number of “F” hospitals fell to three from five in spring. {The article identifies those hospitals.]
- and
- “When the FDA approved daraxonrasib for metastatic pancreatic cancer Aug. 26, some in oncology expected access to remain concentrated at academic medical centers. Nearly three months later, leaders at seven organizations say patients at many cancer centers, including community sites, are starting the drug within one to two weeks. [The article summarize interviews with these leaders.]
- “Instead, the remaining access barriers have proven to be largely administrative. The drug’s rollout is changing outpatient workflows and raising questions about specialty pharmacy strategy, referrals and treatment sequencing.”
- Cardiovascular Business tells us,
- “Coronary artery calcium (CAC) tests are a simple, noninvasive way to image and evaluate the calcium deposits in a patient’s coronary arteries. However, according to a new message from the American Heart Association (AHA), these tests are “not necessary for everyone.”
- “The AHA does not recommend broad based use of the CAC test for screening,” Manesh R. Patel, MD, volunteer president of the AHA and cardiology chief at Duke University School of Medicine, said in a statement. “The association recommends it as a decision aid for people at borderline or intermediate risk for atherosclerotic cardiovascular disease or heart and blood-vessel disease caused by the buildup of cholesterol-containing plaque in the arteries—but only when the decision about whether to use drug therapy to lower risk is uncertain. It is a tiebreaker test.”
- “Guidelines developed by the AHA and American College of Cardiology (ACC) do support the use of CAC scoring for many at-risk patients, especially when there is uncertainty about whether or not cholesterol-lowering therapies or additional medical imaging may be necessary. More specifically, calcium findings are recommended to help guide treatment decisions for men 40 years or older and women 45 years old or older with a borderline or intermediate risk of experiencing a heart attack or stroke in the next decade.”
- The Washington Post lets us know,
- “Hit the gym or lose your muscle. That’s the warning many people hear when starting a GLP-1 weight-loss drug.
- “Now, researchers in Australia have some of the first rigorous evidence that pumping iron is worth the effort, though perhaps not for the reason most people expect.
- “Weight training preserved only a sliver of muscle. Its bigger payoff was strength.” * * *
- “Strength is a more important outcome than muscle mass, because it relates to function and frailty,” said Daniel Green, an exercise physiologist at the University of Western Australia who led the study.”
- Health Day informs us,
- “Simple visual tests could provide an early warning flag for brain decline, a new study says.
- “People with mild cognitive impairment responded more slowly and performed worse on visual tests that required them to remember and process conflicting information, researchers reported recently in the journal Brain Sciences.
- “Our study shows that reaction times can provide valuable information about cognitive function that may be missed by conventional memory testing,” senior researcherShahina Pardhan, director of the Vision and Eye Research Institute at Anglia Ruskin University in the U.K., said in a news release.”
- and
- “Chronic hand eczema (CHE) is common, impacting nearly 1 in 10 U.S. adults, according to a study published online Nov. 11 in JAMA Dermatology.
- “Raj Chovatiya, M.D., Ph.D., from the Rosalind Franklin University of Medicine and Science in North Chicago, and colleagues estimated the prevalence of chronic hand eczema in U.S. adults. The analysis included 10,636 participants in the Chronic Hand Eczema Epidemiology, Care, and Knowledge of Real-Life Burden in the U.S. online survey.” * * *
- “These findings from a large epidemiological study estimating the prevalence of CHE in U.S. adults suggest that CHE is a common skin disease in the United States and emphasize the need for more comprehensive research to accurately quantify the burden of CHE and inform evidence-based prevention and management strategies,” the authors write.”
- Beckers Behavioral Health points out,
- “The share of U.S. high school students reporting persistent sadness or hopelessness fell from 42.3% in 2021 to 33.3% in 2025, according to an analysis of federal survey data published Nov. 18 by the Institute for Family Studies.
- “Several statistics indicate a broad reversal in youth mental health metrics since the peak of the pandemic-era crisis, the report said.
- ‘The analysis, written by Gallup Principal Economist Jonathan Rothwell, PhD, draws primarily on the CDC’s Youth Risk Behavior Survey and Substance Abuse and Mental Health Services Administration data. It argues that nearly every measure of adolescent mental health has improved over the past four years, reversing a decline that began around 2011.”
- Per Fierce Pharma,
- “After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb is offering an early peek that appears to bode well for the high-stakes data drops ahead, even as the fine details remain hazy.
- “BMS on Wednesday rolled out preliminary findings from its late-stage Adept program, which is assessing its Cobenfy cocktail of xanomeline and trospium chloride—approved in schizophrenia back in 2024—as a treatment for patients with psychosis associated with Alzheimer’s disease.
- “The first look at the results comes courtesy of the 12-week open-label period of Bristol’s Adept-1 study, plus a yearlong open-label extension trial coded Adept-3, with Cobenfy tied to improvements in hallucinations and delusions, as well as overall disease severity, in both. BMS shared the data as part of the Clinical Trials on Alzheimer’s Disease conference this week in Boston.”
- Genetic Engineering and Biotechnology News adds,
- “Twelve years after a widely quoted Cleveland Clinic study showed a staggering 99.6% failure rate for Alzheimer’s disease clinical candidates, the percentage has hardly budged.
- “But ImmunoBrain, an 11-year-old company, has generated early-stage clinical data showing success for a first-of-its-kind, immunotherapy-based approach to treating Alzheimer’s that goes beyond aiming at the two most common targets, amyloid plaques and tau neurofibrillary tangles.
- I”mmunoBrain develops treatments intended to address Alzheimer’s and other neurodegenerative diseases by restoring the body’s peripheral immune system to facilitate brain protection and repair. The company uses a novel approach that targets the peripheral immune system to break the vicious cycle between neuroinflammation developed in the brain with neurodegenerative diseases and the progressive decline in peripheral immune function that together derives disease progression.”
- Earlier this week Fierce Pharma unveiled its 2026’s Fiercest Women in Life Sciences.
From the U.S. healthcare business and artificial intelligence front,
- Beckers Hospital Review reports,
- “Health systems can no longer rely on acquiring hospitals and expanding traditional service lines to secure their financial futures. As reimbursement pressures mount and consolidation accelerates, CFOs are rethinking where care is delivered, which services should be centralized and how to grow without adding unsustainable costs.
- “We cannot replicate what has not worked in the past,” Carlos Bohorquez, CFO of UC San Diego Health, said during a Nov. 3 panel at Becker’s 14th Annual CEO + CFO Roundtable in Chicago.
- “Mr. Bohorquez warned that consolidation does not automatically translate into efficiencies, particularly when health systems maintain duplicative leadership structures, staffing and specialty services after bringing hospitals together. On paper, many M&As set out to achieve certain economies of scale, but the reality is that costs often get inflated along the way.” * * *
- “We need to be thoughtful as far as where the services should reside, at what level, and that it really is an integrated model that feeds itself as far as what’s the right level of care at the right site and where certain services should be provided,” he said. “Otherwise, we’ll end up with five cardiology programs and little volume at each site, or limited volume, and it’s not going to work.”
- “Brian Devine, CFO of Allegheny Health Network, echoed that sentiment, arguing that health systems need to move away from capital-intensive hospital models toward more flexible approaches that align care delivery with reimbursement and patient needs.”
- Beckers Payer Issues relates,
- “UnitedHealthcare has named Joe Clark CEO of Surest, the insurer’s fastest-growing commercial health plan.
- “Mr. Clark first joined the company in 2021 and most recently served as CFO of the insurer’s employer-sponsored and individual market business.
- “Surest, an employer-based plan formerly known as Bind Benefits, was founded in 2016 and rebranded after UnitedHealthcare expanded its majority ownership stake in the company in 2022. The plan offers transparent pricing for care, no deductibles and digital shopping services to more than one million members.”
- MedCity News tells us,
- “Teladoc Health, a virtual care company, announced at the HLTH Conference on Tuesday that it is giving employers a new option to contribute toward the cost of GLP-1 medications outside of traditional pharmacy benefits.
- “The New York City-based company offers virtual medical care, mental health, chronic condition management and other services.
- “The new offering allows employers to help their employees access FDA-approved GLP-1 medications from both Eli Lilly and Novo Nordisk. With the offering, employers set a fixed contribution per employee per fill for each plan year. Employees then pay the remaining balance.”
- Fierce Healthcare adds,
- “Direct-to-consumer health companies Noom and Hims & Hers are making a play for the booming peptide market as the federal government loosens restrictions on compounded treatments.
- “The companies are betting that peptides could be the next big thing in consumer health. For Noom, the new peptide offering extends the company’s business beyond weight loss into the broader longevity and wellness market. Hims & Hers signaled months ago that it was ready to tap into the multi-billion-dollar peptide market.
- “Federal policy shifts and U.S. Food and Drug Administration enforcement discretion around compounded peptides have opened new pathways for telehealth and compounding pharmacies.
- “On Tuesday, Noom launched OpenRx as a separate peptide and preventive health brand. At launch, OpenRx offers two injectable options: sermorelin, a peptide frequently prescribed for muscle support, and NAD+, a coenzyme frequently prescribed for energy. OpenRx also offers two oral dissolvable tablet options: the first formulation combines the peptides PT-141 and oxytocin with tadalafil to support sexual health. The second ODT formulation is the peptide oxytocin to support intimacy.
- “Noom says it plans to expand into other areas including recovery, muscle health, skin, gut health and sleep. Peptides are small pieces of protein that occur naturally in the body and help control functions such as growth, healing and appetite.”
- BioPharma Dive informs us,
- “Isomorphic Labs, a spinout from Alphabet trying to “reimagine” drug discovery with the use of artificial intelligence, raised $5 billion in a Series C financing led by Greenoaks and Sequoia Capital.
- “Alphabet offered “continued significant investment” in the funding round, which also included participation from existing investors and new ones such as Andreesen Horowitz, Isomorphic said Tuesday. The financing follows a $2.1 billion Series B announced in May.
- “The money will help Isomorphic as it attempts to ultimately move from developing AI models to bringing medicines to the clinic. The London-based company said it also expects to be able to “expand deeper into new biology.”
- Per MedTech Dive,
- “Diabetes tech firms Senseonics and Beta Bionics launched an integration this week of their glucose sensors and insulin pumps.
- “Senseonics makes a continuous glucose monitor that can be implanted for up to a year, called Eversense 365. That device is now compatible with Beta Bionics’ iLet Bionic Pancreas automated insulin delivery system.
- “The integration follows a partnership that the two companies struck in September. In the future, they plan to also pair Senseonics’ one-year CGM with Beta Bionics’ new tubeless patch pump, called Mint.”
- and
- “Science Corporation said Tuesday it has raised $400 million to commercialize its brain-computer interface in Europe and to prepare to launch the device in the U.S.
- “The Series D funding round positions Science to expand the availability of its Prima BCI device, which received a CE mark and launched in Europe in July as a treatment for vision loss.
- “Science, which aims to reach the U.S. market via the humanitarian device exemption pathway, raised $230 million in March and has tapped investors for more than $900 million in total.”
